Merrill maintains Amgen at neutral

Amgen Inc. was given a neutral rating by Merrill Lynch analyst Eric Ende. Roche announced CERA's filing for dialysis will occur in 2006 and for cancer in 2009. The delay reduces the risk that CERA will erode Amgen's EPO market in the near term. Merrill sees little potential for earnings-per-share upside in 2006, with few meaningful catalysts until the second half of the year, and an overhang from the patent battle. Shares of the Thousand Oaks, Calif., biotechnology company were up $3.30, or 4.53%, at $6.19 on volume of 34,443,202 shares versus the three-month running average of 7,992,620 shares. (Nasdaq: AMGN)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.